Clinical efficacy of tirofiban versus argatroban in the treatment of acute ischemic stroke
10.3760/cma.j.cn341190-20240318-00269
- VernacularTitle:替罗非班与阿加曲班治疗急性缺血性脑卒中的效果比较
- Author:
Xiaoyan LIU
1
;
Xiaoxiang PENG
;
Chenyi ZHU
Author Information
1. 湖北省第三人民医院神经内科，武汉 430000
- Keywords:
Brain infarction;
Thrombolytic therapy;
Anticoagulants;
Treatment outcome;
Mortality;
Randomized controlled trial;
Tirofiban;
Argatroban
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(9):1300-1305
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of tirofiban versus argatroban in the treatment of acute ischemic stroke. Methods:This study was a retrospective cohort study. Sixty-eight patients with acute ischemic stroke who were continuously admitted to Department of Neurology of The Third People's Hospital of Hubei Province from August 2022 to September 2023 were divided into tirofiban group ( n = 33) and argatroban group ( n = 35) according to the treatment regimen. Both groups were treated according to their respective treatment protocols for 7 days. Clinical outcomes were assessed based on the modified Rankin Scale (mRS) scores. The excellent clinical outcome (mRS score 0-1 points), good clinical outcome (mRS score 0-2 points), symptomatic intracranial hemorrhage, and mortality rates were compared between the two groups at 90 days post-treatment. Results:In the tirofiban group, the proportion of excellent clinical outcomes was 30.3% (10/33), which was significantly lower than the 65.7% (23/35) in the argatroban group (χ2 = 8.53, P = 0.003). However, the difference in the proportion of good clinical outcomes between the two groups was not statistically significant [54.5% (18/33) vs. 74.3% (26/35), χ2 = 2.90, P = 0.089]. There were no statistically significant differences between the two groups regarding symptomatic intracranial hemorrhage and mortality rates (both P > 0.05). Conclusion:For patients with acute ischemic stroke, the use of tirofiban or argatroban is effective and safe. Patients treated with argatroban are more likely to achieve excellent clinical outcomes; however, larger randomized controlled trials are needed for further confirmation.
